Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms

Journal of Personality Disorders

Volumn 23, Issue 2, 2009, Pages 156-174

  Mercer, Deanna ^a,c   Douglass, Alan B ^a   Links, Paul S ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PHENELZINE; TOPIRAMATE; TRANYLCYPROMINE; TRIFLUOPERAZINE; VALPROIC ACID DERIVATIVE;

AGGRESSION; ANGER; ARTICLE; BEHAVIOR THERAPY; BORDERLINE STATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; HUMAN; META ANALYSIS; MOOD DISORDER; PEER REVIEW; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

AFFECT; ANGER; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; DEPRESSION; HUMANS; IMPULSIVE BEHAVIOR; INTERPERSONAL RELATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 65249108333     PISSN: 0885579X     EISSN: 0885579X     Source Type: Journal    
DOI: 10.1521/pedi.2009.23.2.156     Document Type: Article

References (79)

1. Akiskal, H. S. (2004). Demystifying borderline personality: Critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiatrica Scandinavica, 110, 401-407.
2. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition Text Revision)
3. American Psychiatric Association Practice, Guide. (2001). Practice guideline for the treatment of patients with borderline personality disorder. American psychiatric association. American Journal of Psychiatry, 158, 1-52.
4. Bateman, A., & Fonagy, P. (1999). Effectiveness of partial hospitalization in the treatment of borderline personality disorder: A randomized controlled trial. American Journal of Psychiatry, 156, 1563-1569.
5. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4, 561- 571.
6. Binks, C. A., Fenton, M., McCarthy, L., Lee, T., Adams, C. E., & Duggan, C. (2006). Pharmacological interventions for people with borderline personality disorder. Cochrane Database of Systematic Reviews(1), CD005653.
7. Bogenschutz, M. P., & George Nurnberg, H. (2004). Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 104-109.
8. Coccaro, E. F. (1998). Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects. Journal of Clinical Psychiatry, 59, 30-35; discussion 36-37.
9. Coccaro, E. F., Harvey, P. D., Kupsaw-Lawrence, E., Herbert, J. L., & Bernstein, D. P. (1991). Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. Journal of Neuropsychiatry & Clinical Neurosciences, 3, S44-51.
10. Coccaro, E. F., & Kavoussi, R. J. (1997). Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Archives of General Psychiatry, 54, 1081-1088.
11. Cornelius, J. R., Soloff, P. H., Perel, J. M., & Ulrich, R. F. (1993). Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. American Journal of Psychiatry, 150, 1843-1848.
12. Cowdry, R. W., & Gardner, D. L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry, 45, 111-119.
13. de la Fuente, J. M., & Lotstra, F. (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology, 4, 479-486.
14. Dimeff, L. A., McDavid, J., & Linehan, M. M. (1999). Pharmacotherapy for borderline personality disorder: A review of the literature and recommendations for treatment. Journal of Clinical Psychology in Medical Settings, 6, 113- 138.
15. First, M. B., Spitzer, R. L., & Gibbon, M. (1996). Structured clinical interview for dsm iv axis i disorders. New York: Biometric Research New York State Psychiatric Institute.
16. Frankenburg, F. R., & Zanarini, M. C. (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar ii disorder: A double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry, 63, 442- 446.
17. Goldberg, S. C., Schulz, S. C., Schulz, P. M., Resnick, R. J., Hamer, R. M., & Friedel, R. O. (1986). Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Archives of General Psychiatry, 43, 680-686.
18. Grootens, K. P., & Verkes, R. J. (2005). Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry, 38, 20-23.
19. Gunderson, J. C., Kolb, J. E., & Austin, V. (1981). The diagnostic interview for borderline patients. American Journal of Psychiatry, 138, 896-903.
20. Gunderson, J. G., Weinberg, I., Daversa, M. T., Kueppenbender, K. D., Zanarini, M. C., Shea, M. T., et al. (2006). Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. American Journal of Psychiatry, 163, 1173-1178.
21. Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry, 23, 56-62.
22. Hedberg, D. L., Houck, J. H., & Glueck, B. C., Jr. (1971). Tranylcypromine-trifluoperazine combination in the treatment of schizophrenia. American Journal of Psychiatry, 127, 1141-1146.
23. Hollander, E., Allen, A., Lopez, R. P., Bienstock, C. A., Grossman, R., Siever, L. J., et al. (2001). A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry, 62, 199-203.
24. Hollander, E., Tracy, K. A., Swann, A. C., Coccaro, E. F., McElroy, S. L., Wozniak, P., et al. (2003). Divalproex in the treatment of impulsive aggression: Efficacy in cluster b personality disorders. Neuropsychopharmacology, 28, 1186-1197.
25. Joyce, P. R., Mulder, R. T., Luty, S. E., Mc- Kenzie, J. M., Sullivan, P. F., & Cloninger, R. C. (2003). Borderline personality disorder in major depression: Symptomatology, temperament, character, differential drug response, and 6-month outcome. Comprehensive Psychiatry, 44, 35-43.
26. Klein, D. F. (1967). Importance of psychiatric diagnosis in prediction of clinical drug effects. Archives of General Psychiatry, 16, 118-126.
27. Koenigsberg, H. W., Harvey, P. D., Mitropoulou, V., New, A. S., Goodman, M., Silverman, J., et al. (2001). Are the interpersonal and identity disturbances in the borderline personality disorder criteria linked to the traits of affective instability and impulsivity? Journal of Personality Disorders, 15, 358- 370.
28. Koenigsberg, H. W., Reynolds, D., Goodman, M., New, A. S., Mitropoulou, V., Trestman, R. L., et al. (2003). Risperidone in the treatment of schizotypal personality disorder. Journal of Clinical Psychiatry, 64, 628-634.
29. Koons, C. R., Robins, C. J., Tweed, J., Lynch, T. R., Gonzalez, A. M., Morse, J. Q., et al. (2001). Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy, 32, 371-390.
30. Lam, R. W., & Kennedy, S. H. (2005). Using metaanalysis to evaluate evidence: Practical tips and traps. Canadian Journal of Psychiatry-Revue Canadienne de Psychiatrie, 50, 167-174.
31. Leone, N. F. (1982). Response of borderline patients to loxapine and chlorpromazine. Journal of Clinical Psychiatry, 43, 148-150.
32. Lieb, K., Zanarini, M. C., Schmahl, C., Linehan, M. M., & Bohus, M. (2004). Borderline personality disorder. Lancet, 364, 453-461.
33. Linehan, M. M., Armstrong, H. E., Suarez, A., Allmon, D., & Heard, H. L. (1991). Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry, 48, 1060-1064.
34. Linehan, M. M., Dimeff, L. A., Reynolds, S. K., Comtois, K. A., Welch, S. S., Heagerty, P., et al. (2002). Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug & Alcohol Dependence, 67, 13-26.
35. Linehan, M. M., Schmidt, H., 3rd, Dimeff, L. A., Craft, J. C., Kanter, J., & Comtois, K. A. (1999). Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. American Journal on Addictions, 8, 279-292.
36. Links, P. S., Boggild, A., & Sarin, N. (2001). Psychopharmacology of personality disorders: Review and emerging issues. Current Psychiatry Reports, 3, 70-76.
37. Links, P. S., Eynan, R., Heisel, M. J., Barr, A., Korzekwa, M., McMain, S., et al. (2007). Affective instability and suicidal ideation and behavior in patients with borderline personality disorder. Journal of Personality Disorders, 21, 72-86.
38. Links, P. S., Steiner, M., Boiago, I., & Irwin, D. (1990). Lithium therapy for borderline patients: Preliminary findings. Journal of Personality Disorders, 4, 173-181.
39. Lipman, R. S., Covi, L., & Shapiro, A. K. (1979). The hopkins symptom checklist (hscl)-factors derived from the hscl-90. Journal of Affective Disorders, 1, 9-24.
40. Loew, T. H., Nickel, M. K., Muehlbacher, M., Kaplan, P., Nickel, C., Kettler, C., et al. (2006). Topiramate treatment for women with borderline personality disorder: A double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 26, 61-66.
41. Markovitz, P. J. (2004). Recent trends in the pharmacotherapy of personality disorders. Journal of Personality Disorders, 18, 90-101.
42. McNair, D. M., Lorr, M., & Droppleman, L. F. (1981). Edits manual for the profile of mood states (poms).
43. Montgomery, S. A., & Montgomery, D. (1982). Pharmacological prevention of suicidal behaviour. Journal of Affective Disorders, 4, 291-298.
44. Newton-Howes, G., & Tyrer, P. (2003). Pharmacotherapy for personality disorders. Expert Opinion on Pharmacotherapy, 4, 1643-1649.
45. Nickel, M. K., Loew, T. H., & Gil, F. P. (2007). Aripiprazole in treatment of borderline patients, part II: An 18-month followup. Psychopharmacology, 191, 1023- 1026.
46. Nickel, M. K., Muehlbacher, M., Nickel, C., Kettler, C., Pedrosa Gil, F., Bachler, E., et al. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. American Journal of Psychiatry, 163, 833-838.
47. Nickel, M. K., Nickel, C., Kaplan, P., Lahmann, C., Muhlbacher, M., Tritt, K., et al. (2005). Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biological Psychiatry, 57, 495-499.
48. Nickel, M. K., Nickel, C., Mitterlehner, F. O., Tritt, K., Lahmann, C., Leiberich, P. K., et al. (2004). Topiramate treatment of aggression in female borderline personality disorder patients: A doubleblind, placebo-controlled study. Journal of Clinical Psychiatry, 65, 1515- 1519.
49. Nose, M., Cipriani, A., Biancosino, B., Grassi, L., & Barbui, C. (2006). Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials. International Clinical Psychopharmacology, 21, 345-353.
50. Parsons, B., Quitkin, F. M., McGrath, P. J., Stewart, J. W., Tricamo, E., Ocepek- Welikson, K., et al. (1989). Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacology Bulletin, 25, 524-534.
51. Pfohl, B., Blum, N., & Zimmerman, M. (1995). Structured interview for DSM-IV personality: Sidp-IV. Iowa City: University of Iowa Department of Psychiatry.
52. Pfohl, B., & Zimmerman, M. (1989). Structured interview for the diagnosis of DSM III-R personality disorders.
53. Philipsen, A., Schmahl, C., & Lieb, K. (2004). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry, 37, 196-199.
54. Raj, Y. P. (2004). Psychopharmacology of borderline personality disorder. Current Psychiatry Reports, 6, 225-231.
55. Rifkin, A., Quitkin, F., Carrillo, C., Blumberg, A. G., & Klein, D. F. (1972). Lithium carbonate in emotionally unstable character disorder. Archives of General Psychiatry, 27, 519-523.
56. Rinne, T., van den Brink, W., Wouters, L., & van Dyck, R. (2002). Ssri treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159, 2048-2054.
57. Salzman, C., Wolfson, A. N., Schatzberg, A., Looper, J., Henke, R., Albanese, M., et al. (1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 23- 29.
58. Schulz, S. C. (1998). A double-blind study of risperidone for borderline personality disorder, New Research Abstracts, 1998 Annual Meeting, American Psychiatric Association, Toronto Ontario Canada.
59. Sheehan, D. V., Lecrubier, Y., & Sheehan, K. H. (1998). The mini-international neuropsychiatric interview (mini): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59, 22-33.
60. Simpson, E. B., Yen, S., Costello, E., Rosen,
61. K., Begin, A., Pistorello, J., et al. (2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 379-385.
62. Soler, J., Pascual, J. C., Campins, J., Barrachina, J., Puigdemont, D., Alvarez, E., et al. (2005). Double-blind, placebocontrolled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry, 162, 1221-1224.
63. Soloff, P. H. (2000). Psychopharmacology of borderline personality disorder. Psychiatric Clinics of North America, 23, 169-192.
64. Soloff, P. H., Cornelius, J., George, A., Nathan, S., Perel, J. M., & Ulrich, R. F. (1993). Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry, 50, 377-385.
65. Soloff, P. H., George, A., Nathan, S., Schulz, P. M., Cornelius, J. R., Herring, J., et al. (1989). Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. Journal of Clinical Psychopharmacology, 9, 238-246.
66. Spielberger, C. D. (1991). State-trait anger expression inventory: Professional manual. Odessa, Fla: Psychological Assessment Resources.
67. Spitzer, R. L., & Endicott, J. (1978). Schedule for affective disorders and schizophrenia. New York: New York State Psychiatric Instititute.
68. Tritt, K., Nickel, C., Lahmann, C., Leiberich, P. K., Rother, W. K., Loew, T. H., et al. (2005). Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebocontrolled study. Journal of Psychopharmacology, 19, 287-291.
69. Turner, R. M. (2000). Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice, 7, 413-419.
70. Verheul, R., Van Den Bosch, L. M., Koeter, M. W., De Ridder, M. A., Stijnen, T., & Van Den Brink, W. (2003). Dialectical behaviour therapy for women with borderline personality disorder: 12- month, randomised clinical trial in the netherlands. British Journal of Psychiatry, 182, 135-140.
71. Wilson, A., & Henry, D. A. (1992). Meta-analysis. Part 2: Assessing the quality of published meta-analyses. Medical Journal of Australia, 156, 173-174.
72. World Health Organization. (1997). Composite international diagnostic interview (cidi) version 2.1, Geneva Switzerland.
73. Zanarini, M. C. (2004). Update on pharmacotherapy of borderline personality disorder. Current Psychiatry Reports, 6, 66-70.
74. Zanarini, M. C., & Frankenburg, F. R. (2001). Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849-854.
75. Zanarini, M. C., & Frankenburg, F. R. (2003). Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry, 160, 167-169.
76. Zanarini, M. C., Frankenburg, F. R., Hennen, J., & Silk, K. R. (2003). The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. American Journal of Psychiatry, 160, 274-283.
77. Zanarini, M. C., Frankenburg, F. R., Khera, G. S., & Bleichmar, J. (2001). Treatment histories of borderline inpatients. Comprehensive Psychiatry, 42, 144-150.
78. Zanarini, M. C., Frankenburg, F. R., & Parachini, E. A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65, 903-907.
79. Zanarini, M. C., Gunderson, J. C., & Frankenburg, F. R. (1989). The revised diagnostic interview for borderlines: Discriminating bpd from other axis II disorders. Journal of Personality Disorders, 3, 10-18.